Shares of Bristol Myers Squibb Co. BMY rose 1.39% to $59.62 Friday, on what proved to be an all-around positive trading ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

On track to report initial data from Phase 1/2 clinical trial of PM359 for p47phox CGD in 2025 ---- IND-enabling studies ongoing for PM577 for ...

Receiving admilparant, an oral lysophosphatidic acid receptor 1 antagonist, for 26 weeks lowered percent-predicted FVC ...

Four top stocks have at least a 4% dividend and make sense for investors who may be worried about increased volatility in the ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

Half of all pancreatic cancer patients live less than a year after diagnosis. But researchers say there is potential for ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Merck & Company (MRK – Research Report) and ...

Oppenheimer & Co. Inc. reduced its stake in Bristol-Myers Squibb by 8.1%, selling nearly 19,000 shares in Q4. The ...

In this video, Arvind N. Dasari, MD, MS, discussed the results of the CheckMate 8HW trial in which nivolumab and ipilimumab were compared with nivolumab monotherapy for microsatellite instability-high ...

From breakthrough treatments to AI-driven diagnostics, healthcare is evolving faster than ever. With increasing healthcare ...

Bristol Myers Squibb Co. closed 3.76% short of its 52-week high of $61.10, which the company achieved on January 27th.